Effect of CYP2D6 metabolizer status on the disposition of the (+) and (−) enantiomers of perhexiline in patients with myocardial ischaemia von Inglis, Sally C, Herbert, Megan K, Davies, Benjamin J.L, Coller, Janet K, James, Heather M, Horowitz, John D, Morris, Raymond G, Milne, Robert W, Somogyi, Andrew A, Sallustio, Benedetta C

Volltext

Clinical inhibition of CYP2D6‐catalysed metabolism by the antianginal agent perhexiline von Davies, Benjamin J. L., Coller, Janet K., James, Heather M., Gillis, David, Somogyi, Andrew A., Horowitz, John D., Morris, Raymond G., Sallustio, Benedetta C.

Volltext

Bioorthogonal Decaging Reactions for Targeted Drug Activation von Davies, Sarah, Stenton, Benjamin J, Bernardes, Gonçalo J L

Volltext

Short Call Abstracts von Calvo, S., Donovan, S.E., Dias-Santagata, D., Xu, M., Golchert, J., Homuth, G., Phillips, K., Sippel, R., Burman, K.D., Baloch, Z., Lloyd, R., Poehls, J., Barth, N., Harrell, R.M., Kim, S., Kloos, R.T., Ladenson, P.W., Kennedy, G., Busaidy, N.L., Dadu, R., Ying, A., Li, D., Wang, X., Monga, D., Bhatt, A., Tandon, N., D, P., Wei, W., wang, y., Zhou, Z., Amin, S., Konda, B., Busaidy, N.L., Sexton, J.L., Ciampi, R., Ramone, T., Tacito, A., Torregrossa, L., Elisei, R., Bordenave, L., Zerdoud, S., Catargi, B., Randolph, M.L., Liem, S., Maghami, E., Bondaz, L., Urken, M.L., Amberge, M., Kazahaya, K., Bhatti, T., Baloch, Z., LiVolsi, V.A., Kong, E., Choi, J., Gilbert, M.P., Anderson, S.R., Ma, R., Yu, C., Zhang, L., Yan, F., Chazen, R.S., Kadosh, E., Motin, M., Lieder, I., Tang, Y., Liu, H., Zhang, Y., Chen, L., Yao, X., Chang, K., Iyer, P., Leslie, W.D., Jefford, C., Liu, Y., Gooding, W., Hu, Z., Fedorowicz, G., Anderson, J., Kim, S., Barth, N., Kennedy, G., Comarella, A.P., Villagelin, D., Ward, L., Mishra, A., Makarov, V., Fagin, J., Puxeddu, E., Menicali, E., Nucci, N., Morelli, S., Moretti, S., Wiseman, S.M., Hu, H., Liang, J., Fatourechi, V., Radhamma, R.K., Ledger, G.A., Wang, Y., Li, X.

Volltext